AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

The European Medicines Agency warns that Novo Nordisk's Ozempic and Wegovy may, in rare cases, cause NAION—a serious eye condition that can lead to vision loss. The EMA has asked the company to update ...

Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

Weight-loss drugs are already dropping in price; could they go even lower? - Consumers are now able to pay roughly $500 for ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Omada Health shares climbed after the company made its debut on Nasdaq. The virtual healthcare company started trading shares at $19 on Friday morning, and they jumped 35% to $25.58 by midday. It ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

A new study brings into focus the relationship between diabetic GLP-1 users and the elevated risk of age-related eye disease.

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.